Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Operating Margin: 2021-2025

Historic Operating Margin for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Sep 2025 value amounting to -12.24%.

  • Tarsus Pharmaceuticals' Operating Margin rose 4005.00% to -12.24% in Q3 2025 from the same period last year, while for Sep 2025 it was -23.88%, marking a year-over-year increase of 8459.00%. This contributed to the annual value of -65.90% for FY2024, which is 75463.00% up from last year.
  • Tarsus Pharmaceuticals' Operating Margin amounted to -12.24% in Q3 2025, which was up 43.36% from -21.61% recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Operating Margin peaked at 4,027.12% during Q2 2023, and registered a low of -4,274.56% during Q4 2021.
  • Over the past 3 years, Tarsus Pharmaceuticals' median Operating Margin value was -52.29% (recorded in 2024), while the average stood at 11.52%.
  • Its Operating Margin has fluctuated over the past 5 years, first spiked by 488,517bps in 2022, then slumped by 580,651bps in 2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' Operating Margin (Quarterly) stood at -4,274.56% in 2021, then surged by 412,395bps to -150.61% in 2022, then tumbled by 18,933bps to -339.94% in 2023, then surged by 30,316bps to -36.77% in 2024, then skyrocketed by 4,005bps to -12.24% in 2025.
  • Its last three reported values are -12.24% in Q3 2025, -21.61% for Q2 2025, and -33.55% during Q1 2025.